Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2026HaematologicaOpen Access

P11 | Peripheral Measurable Residual Disease Activity Assessment by Maldi-Tof Mass Spectrometry in Patients With Newly-Diagnosed Multiple Myeloma in the Phase 3 GMMG-Hd7 Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JJJ. X. JinHeidelberg UniversityVGV.R. GindeGerman Cancer Research CenterSHS. HuhnHeidelberg University

Discussion

Loading...

Member takes

Implication

Phase 3 trial evaluates mass spectrometry for monitoring disease activity in multiple myeloma, suggesting improved outcomes.

Key Points

  • The goal is to evaluate the effectiveness of mass spectrometry in assessing minimal residual disease in multiple myeloma patients longitudinally.
  • Serum mass spectrometry performed on samples from 617 patients at multiple timepoints.
  • Measurable residual activity assessed using the EXENT® system.
  • Bone-marrow minimal residual disease evaluated via next-generation flow cytometry.
  • Prognostic impact on progression-free survival analyzed using multivariate Cox models.
  • Mass spectrometry distinguished therapeutic antibodies from patient M-proteins.
  • MS negativity predicted superior progression-free survival, especially during maintenance.
  • Combined MS and MRD assessment improved risk stratification, with double-positive patients showing poorest outcomes.
  • Concordance between MS and MRD increased over time, enhancing overall sensitivity.

Cite This Study

Jin et al. (2026) studied this question.

synapsesocial.com/papers/69e470a4010ef96374d8d8bahttps://doi.org/10.3324/haematol.2026.s2.14035
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study2025
  2. 2Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results2026
  3. 3Mass spectrometry-based proteomics and metabolomics in multiple myeloma: a systematic review of prognostic biomarkers and minimal residual disease monitoring2026
  4. 4Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial2024 · 7 citations
  5. 5Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial2025